198 related articles for article (PubMed ID: 31679120)
1. Pharmacokinetics and Bioequivalence Evaluation of a New Oxycodone Tamper-Resistant Tablet Administered with an Opioid Antagonist in Patients with Chronic Pain.
Luo Z; Miao J; Shu S; Wang Y; Zhu X; Hu C; Shen Y
Clin Drug Investig; 2020 Feb; 40(2):139-148. PubMed ID: 31679120
[TBL] [Abstract][Full Text] [Related]
2. Bioequivalence of oxycodone hydrochoride extended release tablets to marketed reference products OxyContin® in Canada and US.
Gosai P; Ducharme MP; Godfrey AR; Freeman JC; Monif T; Kumar KS; Kumar S; Mudnaik R; Katikaneni P
Int J Clin Pharmacol Ther; 2013 Nov; 51(11):895-907. PubMed ID: 23673291
[TBL] [Abstract][Full Text] [Related]
3. Effect of food on the pharmacokinetics of oxycodone and naltrexone from ALO-02, an extended release formulation of oxycodone with sequestered naltrexone.
Gandelman K; Lamson M; Salageanu J; Bramson C; Matschke K; Malhotra B
Clin Pharmacol Drug Dev; 2015 Sep; 4(5):370-6. PubMed ID: 27137146
[TBL] [Abstract][Full Text] [Related]
4. Dose proportionality and the effects of food on bioavailability of an immediate-release oxycodone hydrochloride tablet designed to discourage tampering and its relative bioavailability compared with a marketed oxycodone tablet under fed conditions: a single-dose, randomized, open-label, 5-way crossover study in healthy volunteers.
Bass A; Stark JG; Pixton GC; Sommerville KW; Zamora CA; Leibowitz M; Rolleri R
Clin Ther; 2012 Jul; 34(7):1601-12. PubMed ID: 22717418
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic Bioequivalence Studies of an Extended-Release Oxycodone Hydrochloride Tablet in Healthy Japanese Subjects Under Fasting and Fed Conditions Without an Opioid Antagonist.
Toyama K; Furuie H; Kuroda K; Ishizuka H
Drugs R D; 2017 Sep; 17(3):363-370. PubMed ID: 28516342
[TBL] [Abstract][Full Text] [Related]
6. Comparing the Effect of Tampering on the Oral Pharmacokinetic Profiles of Two Extended-Release Oxycodone Formulations with Abuse-Deterrent Properties.
Gudin J; Levy-Cooperman N; Kopecky EA; Fleming AB
Pain Med; 2015 Nov; 16(11):2142-51. PubMed ID: 26108255
[TBL] [Abstract][Full Text] [Related]
7. Bioavailability of oxycodone after administration of a new prolonged-release once-daily tablet formulation in healthy subjects, in comparison to an established twice-daily tablet
.
Scheidel B; Maritz MA; Gschwind YJ; Steigerwald K; Guth V; Kovacs P; Rey H
Int J Clin Pharmacol Ther; 2017 Nov; 55(11):881-890. PubMed ID: 28933336
[TBL] [Abstract][Full Text] [Related]
8. A single-dose, 3-way crossover pharmacokinetic comparison between immediate-release oxycodone hydrochloride with aversion technology (IRO-A, Oxecta), IRO-a with Niacin, and Oxycodone Hydrochloride (Roxicodone) in healthy adults under fasting conditions.
Leibowitz MT; Zamora CA; Brzeczko AW; Stark JG
Am J Ther; 2014; 21(2):99-105. PubMed ID: 22357166
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of an Extended-Release, Abuse-Deterrent, Microsphere-in-Capsule Analgesic for the Management of Patients with Chronic Pain With Dysphagia (CPD).
Fleming AB; Carlson DR; Varanasi RK; Grima M; Mayock SP; Saim S; Kopecky EA
Pain Pract; 2016 Mar; 16(3):334-44. PubMed ID: 25639548
[TBL] [Abstract][Full Text] [Related]
10. Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers.
Smith K; Hopp M; Mundin G; Leyendecker P; Bailey P; Grothe B; Uhl R; Reimer K
Clin Ther; 2008 Nov; 30(11):2051-68. PubMed ID: 19108793
[TBL] [Abstract][Full Text] [Related]
11. Effects of ethanol on the pharmacokinetics of extended-release oxycodone with sequestered naltrexone (ALO-02).
Malhotra BK; Matschke K; Wang Q; Bramson C; Salageanu J
Clin Drug Investig; 2015 Apr; 35(4):267-74. PubMed ID: 25724154
[TBL] [Abstract][Full Text] [Related]
12. Abuse potential, pharmacokinetics, pharmacodynamics, and safety of intranasally administered crushed oxycodone HCl abuse-deterrent controlled-release tablets in recreational opioid users.
Harris SC; Perrino PJ; Smith I; Shram MJ; Colucci SV; Bartlett C; Sellers EM
J Clin Pharmacol; 2014 Apr; 54(4):468-77. PubMed ID: 24243216
[TBL] [Abstract][Full Text] [Related]
13. A multicenter, 12-month, open-label, single-arm safety study of oxycodone-hydrochloride/naltrexone-hydrochloride extended-release capsules (ALO-02) in patients with moderate-to-severe chronic noncancer pain.
Arora S; Setnik B; Michael D; Hudson JD; Clemmer R; Meisner P; Pixton GC; Goli V; Sommerville KW
J Opioid Manag; 2014; 10(6):423-36. PubMed ID: 25531960
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics, tolerability, and safety of intranasal administration of reformulated OxyContin(®) tablets compared with original OxyContin (®) tablets in healthy adults.
Perrino PJ; Colucci SV; Apseloff G; Harris SC
Clin Drug Investig; 2013 Jun; 33(6):441-9. PubMed ID: 23677743
[TBL] [Abstract][Full Text] [Related]
15. Intranasal abuse potential of an abuse-deterrent oxycodone formulation compared to oxycodone immediate release and placebo in nondependent, recreational opioid users.
Setnik B; Schoedel K; Bartlett C; Dick C; Hakim N; Geoffroy P
J Opioid Manag; 2017; 13(6):449-464. PubMed ID: 29308591
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic and pharmacodynamic evaluation of oxycodone and naltrexone for the treatment of chronic lower back pain.
Davis MP
Expert Opin Drug Metab Toxicol; 2016 Jul; 12(7):823-31. PubMed ID: 27253690
[TBL] [Abstract][Full Text] [Related]
17. A nasal abuse potential randomized clinical trial of REMOXY® ER, a high-viscosity extended-release oxycodone formulation.
Friedmann N; Marsman MR; de Kater AW; Burns LH; Webster LR
J Opioid Manag; 2018; 14(6):437-443. PubMed ID: 30629280
[TBL] [Abstract][Full Text] [Related]
18. Particle size affects pharmacokinetics of milled oxycodone hydrochloride tablet products following nasal insufflation in nondependent, recreational opioid users.
Raofi S; Kinjo M; Sun D; Li Z; Boyce H; Natarajan K; Frost M; Zhao L; Luke M; Lionberger R; Kelsh D; Kim MJ
Clin Transl Sci; 2021 Sep; 14(5):1977-1987. PubMed ID: 33982418
[TBL] [Abstract][Full Text] [Related]
19. Impact of physical manipulation on in vitro and in vivo release profiles of oxycodone DETERx®: an extended-release, abuse-deterrent formulation.
Kopecky EA; Fleming AB; Noonan PK; Varanasi RK; Grima M; Saim S; Mayock SP
J Opioid Manag; 2014; 10(4):233-46. PubMed ID: 25162603
[TBL] [Abstract][Full Text] [Related]
20. The implications of tamper-resistant formulations for opioid rotation.
Pappagallo M; Sokolowska M
Postgrad Med; 2012 Sep; 124(5):101-9. PubMed ID: 23095430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
